HD Labs Retatrutide 32 mg – Triple-Agonist Injection Pen
Advanced Metabolic • Appetite • Energy Regulation Therapy
HD Labs Retatrutide 32 mg is a next-generation metabolic injectable supplied as a pre-filled subcutaneous injection pen. Retatrutide is a triple-agonist compound acting on GLP-1, GIP, and GCGR pathways, offering a broader metabolic signalling profile compared to traditional single- or dual-agonist therapies.
This advanced formulation is designed to support appetite regulation, weight-management protocols, glucose control, and overall metabolic efficiency within medically supervised environments.
Therapeutic Focus
Appetite suppression and satiety signalling
Weight-management support
Blood glucose regulation
Enhanced energy expenditure via multi-pathway activation
Comprehensive metabolic optimisation
Product Information
Active Ingredient: Retatrutide
Strength: 32 mg
Mechanism: GLP-1 / GIP / GCGR receptor agonist
Form: Solution for injection
Delivery System: Pre-filled pen
Route of Administration: Subcutaneous
Use: Single-patient use only
Quality & Manufacturing
Pharmaceutical-grade formulation
Precision-filled injection system
Manufactured under controlled quality standards
Designed for stability, consistency, and accurate delivery